Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-12
DOI
10.1038/s41467-021-27945-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
- (2021) Petr O. Ilyinskii et al. Science Advances
- Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study
- (2021) Karen Liao et al. PLoS One
- Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles
- (2021) Petr O. Ilyinskii et al. Frontiers in Immunology
- Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
- (2020) Takashi Kei Kishimoto Frontiers in Immunology
- Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
- (2018) Ronit Mazor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis
- (2018) Robert A. LaMothe et al. Frontiers in Immunology
- Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration
- (2018) Amine Meliani et al. Nature Communications
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2016 updated EULAR evidence-based recommendations for the management of gout
- (2016) P Richette et al. ANNALS OF THE RHEUMATIC DISEASES
- Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation
- (2016) Ai-Hong Zhang et al. CELLULAR IMMUNOLOGY
- Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
- (2016) Takashi K. Kishimoto et al. Nature Nanotechnology
- Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
- (2015) J. N. Mahlangu et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- New FDA Draft Guidance on Immunogenicity
- (2014) Ashwin Parenky et al. AAPS Journal
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
- (2014) Roberto A. Maldonado et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
- (2014) Peter E Lipsky et al. ARTHRITIS RESEARCH & THERAPY
- Mammalian target of rapamycin inhibitor-associated stomatitis
- (2013) Christine B Boers-Doets et al. Future Oncology
- Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
- (2013) Herbert SB Baraf et al. ARTHRITIS RESEARCH & THERAPY
- Pegloticase and Chronic Gout--Reply
- (2011) J. S. Sundy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search